Chinese Hepatolgy ›› 2025, Vol. 30 ›› Issue (8): 1138-1141.

• Other Liver Diseases • Previous Articles     Next Articles

Effect of probiotics combined with intermittent blue light therapy on percutaneous bilirubin and immunoglobulin in neonates with hyperbilirubinemia

REN Xiao-tao1, LI Yi1, ZHENG Jie1, ZHAI Meng2   

  1. 1. Department of Neonatology, Mianyang Maternal and Child Health Hospital.Mianyang Children′s Hospital, Mianyang 621000, China;
    2. Department of Neonatology, Yan′an University Xianyang Hospital , Xianyang 712000, China
  • Received:2025-01-20 Published:2025-09-19
  • Contact: ZHAI Meng,Email:249751475@qq.com

PDF (PC)

8

Abstract: Objective To explore the effects of probiotics combined with intermittent blue light therapy on percutaneous bilirubin and immunoglobulin levels in neonates with hyperbilirubinemia. Methods A retrospective analysis was conducted on the clinical data of 123 newborns with hyperbilirubinemia admitted to Mianyang Maternal and Child Health Hospital from October 2022 to October 2023. According to different treatment methods, patients were divided into a control group(n=54) and a combination group(n=69). The control group received intermittent blue light therapy, while the combination group received probiotic bifidobacteria triple active powder combined with intermittent blue light therapy. The clinical efficacy, percutaneous bilirubin levels, T lymphocyte subsets, immunoglobulin (IgM, IgG) levels and total complication rate of hyperbilirubinemia neonates in two groups were compared. Results The effective rate in combination group (98.55%) was higher compared with control group (90.74%) (P<0.05). The transcutaneous bilirubin level in the combination group after treatment was (93.57±24.09)μmol/L, significantly lower than that in the control group (135.21±21.63) μmol/L, P<0.05]. The CD4+ levels and CD4+/CD8+ ratio in the combination group after treatment were (49.61±6.78)% and (2.05±0.54), respectively, which were significantly higher than those in the control group [(28.97±8.21)% and (0.98±0.32), respectively, P<0.05]. The IgM level in the combination group after treatment was (0.71±0.16) g/L, significantly higher than that in the control group (0.47±0.12) g/L, P<0.05]. The total complication rate in combined group was 1.45% (1/69), which was lower compared with control group (12.96%) (7/54) (χ2=4.846, P=0.028). Conclusion Probiotics combined with intermittent blue light therapy can improve the transcutaneous bilirubin levels and immune function of newborns with hyperbilirubinemia, with favorable safety.

Key words: Probiotics, Intermittent blue light therapy, Hyperbilirubinemia, Percutaneous bilirubin, Immunoglobulin